Multi-targeted $^1$H/$^{19}$F MRI unmask specific danger patterns for emerging cardiovascular disorders

Ulrich Flögel$^{1,2,3,}$, Sebastian Temme$^{1,2,3,4,}$, Christoph Jacoby$^{1,3}$, Thomas Oerther$^5$, Petra Keul$^6$, Vera Flocke$^1$, Xiaowei Wang$^7$, Florian Bönner$^3$, Fabian Nienhaus$^3$, Karlheinz Peter$^7$, Jürgen Schrader$^{2,3}$, Maria Grandoch$^8$, Malte Kelm$^{2,3}$ & Bodo Levkau$^6$

Prediction of the transition from stable to acute coronary syndromes driven by vascular inflammation, thrombosis with subsequent microembolization, and vessel occlusion leading to irreversible myocardial damage is still an unsolved problem. Here, we introduce a multi-targeted and multi-color nanotracer platform technology that simultaneously visualizes evolving danger patterns in the development of progressive coronary inflammation and atherothrombosis prior to spontaneous myocardial infarction in mice. Individual ligand-equipped perfluorocarbon nanoemulsions are used as targeting agents and are differentiated by their specific spectral signatures via implementation of multi chemical shift selective $^{19}$F MRI. Thereby, we are able to identify areas at high risk of and predictive for consecutive development of myocardial infarction, at a time when no conventional parameter indicates any imminent danger. The principle of this multi-targeted approach can easily be adapted to monitor also a variety of other disease entities and constitutes a technology with disease-predictive potential.

$^1$Experimental Cardiovascular Imaging, Institute for Molecular Cardiology, Heinrich Heine University, Düsseldorf, Germany. $^2$Cardiovascular Research Institute Düsseldorf (CARID), Heinrich Heine University, Düsseldorf, Germany. $^3$Department of Cardiology, Pneumology and Angiology, University Hospital Düsseldorf, Düsseldorf, Germany. $^4$Department of Anesthesiology, Heinrich Heine University, Düsseldorf, Germany. $^5$Bruker BioSpin, Rheinstetten, Germany. $^6$Institute of Molecular Medicine III, Heinrich Heine University, Düsseldorf, Germany. $^7$Baker Heart and Diabetes Institute, Melbourne, Australia. $^8$Department of Pharmacology and Clinical Pharmacology, Heinrich Heine University, Düsseldorf, Germany. ✉email: floegel@uni-duesseldorf.de
Cardiovascular disease is worldwide a major cause of mortality and morbidity\(^1\) and, thus, has made the identification of patients at high risk for myocardial infarction (MI) or stroke a key challenge. A major driver towards vessel occlusion is vascular thromboinflammation, resulting in the activation of pro-thrombotic and pro-inflammatory functions of endothelial cells, which in turn leads to dysregulation of coagulation, complement, platelet activation, and leukocyte recruitment in the microvasculature\(^2\). For risk assessment and therapeutic decision making, one ideally would like to monitor the entire underlying pathophysiological cascade with early endothelial activation, vascular inflammation, thrombus formation at the arterial wall, and subsequent microembolization, finally culminating into total vessel occlusion and acute MI\(^3,4\). Simultaneous identification of these interlaced processes would require a multi-level approach for timely visualization of the emerging danger patterns at the culprit site of the coronary circulation, causing transition from stable to acute coronary syndromes with plaque formation over erosion to rupture\(^5\). Data of the present study demonstrate that this goal can be achieved within a single imaging session using a novel multi-targeted MRI-based approach.

Among the molecular imaging approaches, fluorine (\(^{19}\text{F}\)) MRI has recently emerged as a promising tool for visualizing disease markers that offer information beyond anatomical alterations. \(^{19}\text{F}\) is an intrinsically sensitive nucleus for MRI\(^6\); there is negligible endogenous \(^{19}\text{F}\) in the body and, thus, no background signal which allows the detection and exact localization of fluorinated materials as ‘hotspots’ by combined \(^{1}\text{H}/^{19}\text{F}\) MRI\(^7\). In addition, there is a family of compounds, perfluorocarbons, which exhibits a very high fluorine pay-load and that is biochemically and physiologically inert\(^8\). Perfluorocarbon nanoemulsions (PFCs) are readily ingested by blood monocytes allowing us and others to track their migration into inflammatory foci in vivo\(^9,10\). Using an ‘active targeting’ approach by equipping PFCs with an \(α\)2-antiplasmin peptide (\(α2\)AP) cross-linking to the developing fibrin network by FXIIIa\(^13,14\), also the occurrence of freshly formed thrombi could lately be monitored in vivo\(^15\).

In the present study, we have raised this approach to the next level for simultaneous detection of multiple specific imaging signatures that we have termed cardiovascular danger patterns. We demonstrate that this allows the reliable identification of arterial vasculature at risk for imminent occlusive thrombosis thus predicting the occurrence of MI in the ‘HypoE’ mouse model\(^16,17\). This diet-induced model of spontaneous MI closely recapitulates human pathophysiology, including the entire cascade of inflammatory coronary plaque development, atherothrombosis, microembolization, and vessel occlusion with subsequent MI. To visualize the individual steps of thromboinflammation in this model, we developed multi-targeted PFCs with distinct spectral properties for concomitant monitoring of major biological hallmarks of disease progression. For the true simultaneous imaging of multiple PFC signals, we further evolved multi chemical shift selective \(^{19}\text{F}\) MRI allowing the time-saving and artefact-free acquisition of, in principle, any number of \(^{19}\text{F}\) resonance frequencies.

**Results**

Early detection of cardiovascular inflammation prior to loss of endothelial integrity. First, we explored whether our approach can identify inflammatory patterns at exquisitely early stages in this mouse model. For this, repetitive injections of neat (untargeted) perfluorocarbon ether emulsions (PFC) together with late gadolinium (Gd) enhancement (LGE) were employed for longitudinal monitoring of infiltrating immune cells and occurrence of ischemia, respectively (see timeline in Supplementary Fig. 1).

Animals received PFCs two days prior to MRI allowing for adequate \(^{19}\text{F}\) loading of immune cells and their subsequent migration into inflammatory foci. LGE was carried out only after \(^{19}\text{F}\) MRI to avoid alterations of \(^{19}\text{F}\) relaxation times impacting on quantification.

Serial \(^{19}\text{F}\) MRI was performed over 15 days as shown in Fig. 1: As early as day 5 after the initiation of atherogenic diet, \(^{19}\text{F}\) signal was detected at the branching site of right common carotid and subclavian artery; an area known as prone to premature plaque development (Fig. 1a, \(^{19}\text{F}\) superimposed in red over anatomical \(^{1}\text{H}\) MRI (greyscale)). Follow-up on day 10 revealed increased PFC depositions in the aortic arch and beginning inflammation at the base of the heart (Fig. 1b, c, left). Of note, no signal enhancement was observed at the site of \(^{19}\text{F}\) signal upon Gd application, excluding any loss of membrane integrity at this time (Fig. 1b, c right (LGE) vs. middle (native)). Five days later (day 15), there was a further increase of \(^{19}\text{F}\) signal at the same site indicative of progressing anular inflammation now associated with a congruent LGE pattern (Fig. 1d); the same was observed in the apex consistent with previous reports on MI location\(^16\) in this model (Supplementary Fig. 2). Post mortem 3D high resolution \(^{1}\text{H}/^{19}\text{F}\) MRI demonstrated that the \(^{19}\text{F}\) label was co-located with the proximal coronary arteries, reflecting infiltration of PFC-loaded immune cells into coronary hotspots within the coronary ostia and aortic valves as classical predilection sites of atherosclerosis (Fig. 1e, left and middle). Similar time courses were regularly observed in all mice from a cohort of six (see below and Supplementary Figs. 3–7).

Subsequent pathohistological analyses combined with ex vivo MRI always and reliably corroborated the in vivo findings and confirmed (i) PFC deposition at the luminal site of the truncus brachiocephalicus and immune cells in the aortic wall on day 5 (Supplementary Fig. 3), (ii) inflammation at the base of the heart without any signs for MI or necrosis on day 10 (Supplementary Fig. 4), (iii) co-localization of immune cells and myocardial scar tissue at an advanced disease stage on day 15 (Supplementary Fig. 5), and (iv) robust detection of \(^{19}\text{F}\) signals irrespective of the individually different disease progression (Supplementary Fig. 6).

Altogether, these results demonstrated that—in a model exhibiting a continuum from coronary inflammation to vessel occlusion and MI—\(^{19}\text{F}\) MRI allowed an early visualization of inflammatory processes in the coronary circulation prior to any signs of structural damage. Passive distribution of emulsion particles (\(\geq 100\) nm) within the tissue can be excluded (→ no LGE), which is an important prerequisite for the specific targeting of epitopes inside the vascular wall. No cardiac \(^{19}\text{F}\) signals whatsoever were observed in mice of the same genotype but without atherogenic diet (Supplementary Fig. 7).

Multi chemical shift selective imaging for artefact-free detection of different PFCs. Next, we turned to the concurrent detection of ongoing thrombotic processes in this model. To this end, we employed ligands specific for markers of early and chronic thrombosis, such as \(α2\)AP\(^15\) and fbn (based on EP-2104R\(^18\)) for targeting of FXIIIa and fibrin, respectively, that we attached to the surface of PFCs with spectral signatures distinct from PFC: perfluorooctyl bromide (PFOB) and perfluoro-1,3,5-trimethylcyclohexane (PFCH), respectively (Fig. 2b left). Importantly, all targeted PFCs were additionally PEGylated for stealth against uptake by monocytes\(^15\) (Supplementary Fig. 8).

For simultaneous, artefact-free and rapid detection of individual PFCs in a single scan, we developed a multi chemical shift selective imaging (mCSSI) sequence as schematically shown in Fig. 2a. It can be considered as a multi-slice 3D rapid acquisition with relaxation enhancement (RARE) variant, in which slice selection is replaced by
frequency selective excitation. Narrow bandwidth excitation is followed by phase encoding of the third dimension and acquisition of the echo train with selective refocusing pulses. Gradient spoiling destroys remaining transverse magnetization at the end of each cycle and the entire procedure is repeated for the number of excitation frequencies within one repetition time. This approach can be applied in principle to any number of frequencies.

This sequence allowed us to specifically detect all individual $^{19}$F signals without any spill-over of neighboring $^{19}$F peaks and to image the three perfluorocarbons by simultaneous acquisition of five distinct $^{19}$F frequencies (Supplementary Table 1 and indicated by colored arrows in Fig. 2b left). As shown in Fig. 2c, $^{19}$F mCSSI enabled artefact-free detection of both separated and mixed emulsions in the same experiment. For PFCE (red), its
Figure 1 Early detection of cardiovascular inflammation and its gradual progression over time by \(^1\text{H}/\(^{19}\text{F}\) MRI. Tracking of PFC-loaded immune cells in the same mouse 5 days (a), 10 days (b–c) and 15 days (d–e) after onset of the diet. \(^{19}\text{F}\) MRI data are superimposed in red over anatomical \(^1\text{H}\) MRI data (greyscale). a First investigation on day 5: Long axis view (left) showing \(^{19}\text{F}\) signal only at the cusp of the aortic arch. The presence of \(^{19}\text{F}\) signal at the branching site of right common carotid and subclavian artery at the brachiocephalic trunk was further confirmed by merging of \(^{19}\text{F}\) and time-of-flight MR angiography data (middle). b–e Follow-up on day 10 revealed increased PFC deposition in the aortic arch and concomitantly onset of inflammation at the base of the heart (left). The dashed rectangle (middle) indicates the perpendicular view illustrated in c. Upon Gd application, in both views no signal enhancement was observed at the site of inflammation (b–c) right (LGE) vs middle (native). d Further check-up on day 15 demonstrated progressing annular infiltration of immune cells at the heart base, now associated with congruent LGE pattern. Thus, tracking of PFC-loaded immune cells early identified myocardial tissue later prone to myocardial ischemia. e Post mortem 3D \(^1\text{H}/\(^{19}\text{F}\) MRI at an isotropic resolution of 40 \(\mu\)m revealed that the \(^{19}\text{F}\) label was primarily co-located with the proximal large coronary arteries at the base of the heart (left and middle, white arrows point to the aortic root; dashed rectangle in the short axis view represents spatial orientation of the long axis view), indicating infiltration of PFC-loaded immune cells into inflammatory hotspots within the coronary ostia and aortic valves as classical predilection sites of atherosclerosis.

A single frequency was used, while for PFOB (cyan) and PFCH (magenta) two frequencies were excited, resulting in two images for each compound (Fig. 2b). An in-house developed software module permitted separation and image reconstruction for each frequency (Fig. 2b right) as well as summation of the individual free induction decays, in order to increase SNR for PFCs with multiple signals (Fig. 2c). There was only a minor effect of homonuclear J modulation on the utilized frequencies (Supplementary Fig. 9), well-known to occur in the linear PFOB skeleton.20 Thus, a reliable quantification for each signal was provided by \(^{19}\text{F}\) mCSSI (Supplementary Fig. 10).

This flexible multi-color detection of distinct PFCs was then applied for visualization of acute and chronic thrombosis. Individual binding characteristics of \(^{2}\text{APPFOB}\) and \(^{18}\text{PFCH}\) were verified in ex vivo generated human thrombi (Supplementary Fig. 11) and validated in a murine model of deep venous thrombosis in vivo (Supplementary Fig. 12). As expected, \(^{2}\text{APPFOB}\) specifically labeled only freshly developed thrombi, while \(^{18}\text{PFCH}\) bound also to thrombi in later stages as robustly detected by \(^{19}\text{F}\) mCSSI (Supplementary Figs. 11b and 12b–c).

Multi-targeted PFCs for thromboinflammatory states in the heart. To longitudinally track the interplay of inflammation and thrombosis in the HypoH mouse we applied a mixture of PPCF, \(^{2}\text{APPFOB}\), and \(^{18}\text{PFCH}\) after onset of the diet. Of note, all emulsions had similar physicochemical properties and comparable \(^{19}\text{F}\) content (Supplementary Fig. 13). Figure 3 illustrates the concurrent monitoring of PFCs targeting inflammation (red), FXIIIa (cyan) and fibrin (magenta) in the same mouse over 15 days, with \(^{19}\text{F}\) mCSSI data superimposed over anatomical \(^1\text{H}\) MRI data (greyscale): On day 5, low level cardiac inflammation was found at the heart base (Fig. 3a) indicative for emerging coronary inflammation without any signs of thrombosis and accompanied by normal heart function (Fig. 3b, left ventricular ejection fraction (LVEF) 67.5%). On day 10, inflammation was clearly enhanced and signals for freshly developed thrombi (FXIIIa + fibrin) as well as chronic thrombi (fibrin only) were detected at sites of inflammation that had been identified on day 5 (Fig. 3a, b+c). This points to pathological tissue alterations without yet functional impairment as LVEF was still preserved (Fig. 3d, LVEF 66.4%). On day 15, however, left ventricular diastolic dilation with severely impaired systolic function had developed (Fig. 3e, LVEF 25.7%) indicative of a functionally relevant MI. These results strongly imply that the initial imaging signals observed within the different fluorine ‘channels’ have identified regions affected by silent thromboinflammation constituting a danger pattern predictive of a subsequent major MI.

Premature detection of pulmonary thromboinflammation turns into right heart failure. Finally, our imaging approach coincidently identified pulmonary thromboembolism as a pathological entity hereto unknown in this model. On day 5, multi-targeted \(^{19}\text{F}\) MRI had identified central (hilus) acute (FXIIIa + fibrin) and chronic thrombi (fibrin only) in the lung along with pulmonary areas exhibiting low grade inflammation (red) (Fig. 4a). Interestingly, left and right ventricular (RV) function were yet uncompromised (Fig. 4b; LVEF 70.4%, RVEF 71.1%), that had sharply changed only 5 days later, where massive RV dilation and functional impairment had developed (Fig. 4c; LVEF 54.6%, RVEF 17.8%), a hallmark of pulmonary thromboembolism. As with MI, the emerging signals in the \(^{19}\text{F}\) ‘channels’ had identified danger patterns indicative for subsequent severe pulmonary thromboembolism (confirmed post mortem by histology, Supplementary Fig. 14).

Occurrence, distribution, and prognostic value of detected PFC signals. Quantification of all \(^{19}\text{F}\) MRI experiments (\(n = 50\) in 23/17/10 mice on days 5/10/15) for occurrence and distribution of detected danger patterns revealed that the predominantly affected sites were the basal part of the left ventricle containing the coronary ostia/aortic valves and the pulmonary system (Fig. 5a). Linear regression analysis for the \(^{19}\text{F}\) signal at day x and cardiac function on day x+5 (i.e. the investigation five days later) for all follow-up measurements with detectable \(^{19}\text{F}\) patterns (\(n = 36\) in 9/17/10 mice on days 5/10/15) revealed an excellent correlation (Fig. 5b). This strongly indicates that simultaneous visualization of different danger patterns by multi-targeted \(^1\text{H}/\(^{19}\text{F}\) MRI can be successfully used to predict further functional impairment.

Discussion
Our findings demonstrate that multi-targeted PFCs allow the reliable identification of still silent but prognostically highly relevant thromboinflammation prior to any subsequent ischemic or thromboembolic event. By concurrent detection of several hallmarks of disease progression, it maps the entire transition from beginning coronary inflammation to microembolization, vessel occlusion and MI (Fig. 6). In principle, other disease entities, target epitopes or cell types could be approached by the same technology assuming the design of suitable ligands e.g. against neutrophils and/or platelet-leukocyte aggregates. Thus, the presented approach provides a general and versatile platform for molecular imaging with a diversity that cannot be offered by any other whole-body imaging technique at this time. The mCSSI sequence allows a highly variable spectral readout and simultaneous detection of several different targeting agents taking advantage of the broad chemical shift range for \(^{19}\text{F}\) (\(-400\) vs. \(-10\) ppm for \(^1\text{H}\)). Although multispectral imaging efforts have been undertaken before and are not limited to MRI21–23, all of the
reported attempts\textsuperscript{24–27} do not offer the flexibility and specificity of the in situ multi-targeting approach validated in our study.

The developed sequence is in principle applicable to any number of frequencies. Thus, we already identified another PFC, i.e. perfluoro[(tert-butyl)cyclohexane], with a clearly separated resonance frequency (Supplementary Fig. 15 top) as additional ‘color’. In proof-of-concept experiments, we verified whether this could be exploited to also visualize another key player in cardiovascular
thrombomodulation: Since acute arterial thrombosis is usually platelet-rich, we employed as targeting ligand a unique single-chain antibody (scFv28), that specifically binds to the activated conformation of GPIIb/IIIa and thus to activated platelets. As demonstrated in Supplementary Fig. 15 middle and bottom, this enabled us to also track the progressive accumulation of activated platelets in diet-exposed mice. Importantly, these experiments corroborated pulmonary thrombosis as up to now unknown pathological characteristic in our mouse model, since we observed substantial platelet aggregation not only in the heart but also in the lung of mice over time (Supplementary Fig. 15 middle and bottom).

The toolbox provided by the present study thus holds the potential to map the transition from stable to unstable coronary syndromes covering the entire cascade from local inflammation, subsequent platelet adhesion, microembolization, and thromboembolism finally culminating in MI. The full encompassment of this process will allow the exact characterization of the ongoing disease state which will not only be useful for mechanistic studies in basic research but also to monitor the effectiveness of novel anti-inflammatory approaches and cellular targets to treat coronary artery disease29. Our approach holds as well translational promise for tailored patient therapy: The precise identification in which stage of this pathophysiological sequence the patient is currently in clearly goes beyond exclusive plaque recognition with surrogate parameters of inflammation and/or destabilization of the vascular wall as provided by established clinical imaging techniques. These include adverse coronary plaque characteristics and overall calcified plaque burden30, microcalcification using Nat31, enhanced glucose turnover and activated macrophages32, high intensity plaques in MRT33, activation of perivascular fat34, and direct characterization of the arterial wall by invasive approaches35,36.

Unfortunately, the acuity of inflammation within atherosclerotic plaques not always matches metabolic turnover or degree of plaque activation and exhibits varying specificity depending on the vessel region32,37. Furthermore, the diagnostic triad of symptoms, changes in ECG, and elevation of troponin has been shown to reliably identify patients in whom the transition from stable coronary syndromes to acute coronary myocardial damage has already occurred38,39. Similarly, microembolization currently is only detectable at late stage in MRI as microvascular obstruction40. Thus, none of these imaging or laboratory-based approaches can fully map the progressive continuum of the entire spectrum of danger patterns indicating the destabilization of arterial culprit lesions with simultaneous detection of vascular inflammation, local atherothrombosis, distal microembolization culminating in thromboembolic events such as acute MI or stroke in a single investigation.

Of course, additional investigations are needed to show that the PFC modifications carried out for specific targeting (PEGylation, ligand equipment) maintain the required safety profile for human use. Several untargeted PFCs have already been evaluated in clinical trials as artificial blood substitutes (e.g. perfluoron)38,42. Although promising the application of PFCs for this purpose did not really take off, but this was less related to unexpected side effects than that they were not better than the standard of care, i.e. blood42,43. Apart from that, anti-PEG antibodies in patients could be a problem for administration of PEGylated contrast agents14. On the other hand, PEG is frequently incorporated into drug formulations to improve therapeutic efficacy and in 2020, there were 21 PEGylated drugs approved by the FDA and over 20 others in clinical trials45. Nevertheless, much effort is currently undertaken to explore the capacity of other polymers to suppress unspecific nanoparticle uptake as candidates with comparable or superior properties to PEG46,47. The modifications made to the nanoparticles may also impact on excretion pathways and biological half-life of the targeted PFCs. It is generally accepted that PFCs are released from the organism by exhalation via the lung which is consistent with the observation that the excretion rate primarily depends on their vapor pressure and permeability through the membrane48. However, also PFC transit to the gut has been observed, but this seems to be of minor relevance for humans and non-rodent species49. Importantly, there are recent reports about quickly clearing and more sustainable PFC formulations50,51, which will be helpful for bridging the gap between experimental animal studies and human applications. Nevertheless, doses and biological half-lives have to be specifically tailored for human use, but this is clearly beyond the scope of the present study and has to be adjusted in clinical trials.

In summary, PFCs with unique spectral signatures can be equipped with specific targeting ligands and utilized to simultaneously track loco-regional alterations of different specific danger patterns by multi chemical shift selective 19F MRI. Using a murine model of atherothrombotic MI mimicking the human situation, we demonstrate that this technology can be applied to serial in vivo imaging of the entire pathophysiological cascade resulting in MI and heart failure and furthermore to identify hereto unknown pathological entities in already well-characterized animal models. Of note, human scanners can readily be equipped with 19F interfaces52,53 and improved scanning algorithms54, coil design55 and relaxometry of PFCs56 will facilitate the transmission of preclinical high field findings to the clinical setting. Provided that possible side-effects as discussed above can be overcome, our approach thus offers a potentially translational perspective for identifying patients at risk for myocardial infarction, stroke, or pulmonary thromboembolism but for whom there is no anatomic correlate of risk in conventional diagnosis, allowing for individualized, informed interventions. In addition to more precisely identify the transition from stable to acute vascular disorders, our MRI-based multi-targeted nanotracer platform enables the opportunity to detect early inflammatory changes in plaque formation allowing primary prevention and to monitor effectiveness of novel anti-inflammatory targets and therapies overall enhancing the option
of individualized precision medicine in disorders of vascular inflammation.

**Methods**

**Chemicals and reagents**

**Chemicals.** Cholesterol-PEG<sub>2000</sub>-maleimide (Nanocs); Na<sub>2</sub>HPO<sub>4</sub>, NaH<sub>2</sub>PO<sub>4</sub>, glycerol (Carl Roth GmbH); thrombin, ADP (Sigma Aldrich); E80S (Lipoid GmbH); perfluoro-15-crown-5 ether (PFCE), perfluoro-1,3,5-trimethylcyclohexane (PFCH), perfluorooctyl bromide (PFOB), diblock, i.e. F<sub>6</sub>H<sub>10</sub>, perfluoro-n-hexyl decane (Abcr chemicals).

**Buffer:** Phosphate glycerol buffer (3 mM NaH<sub>2</sub>PO<sub>4</sub>, 7 mM Na<sub>2</sub>HPO<sub>4</sub>, glycerol 2.5% m/v, pH 7.4), phosphate buffer (PBS, CarlRoth). **Targeting peptides:** Peptides which were derived from α<sub>2</sub>-antiplasmin (∆α<sub>2</sub><sup>AP</sup>) = Ac–Gly–Asn–Gln–Glu–Gln–Val–Ser–Pro–Leu–Thr–Leu–Leu–Lys(Cys)–Trp–Lys<sup>13,15</sup>) and a peptide which was modified on the basis of EP2104-K<sup>19</sup> (here called fbn = Tyr–D-Glu–Cys–Hyp–Tyr[3-Cl]–Gly–Leu–Cys–Tyr–Ile–Gly–Gly–Gly–Gly–Gly–Cys) were utilized for targeting. As control for α<sub>2</sub><sup>AP</sup>, we used a peptide where the glutamic acid at position Q3 which is cross-linked to the fibrin network was replaced by alanine. The control peptide for fbn (FAM–Ser–Asp–Gly–Gly–Als–Asn–Leu–Gly–Gly–Ile–Gly–Gly–Gly–Cys) was generated by replacing and randomizing all of the amino acids which are responsible for fibrin binding<sup>26</sup>. All peptides were commercially manufactured (Genaxxon Bioscience) and fbn and its control were equipped with an additional C-terminal GGG-Cys tag and a carboxyfluorescein at the N-terminus to enable fluorescence imaging. The FXIIIa specific peptide α2AP and its control contained an additional Cys on the ε-amino group of K13 and the carboxyfluorescein was conjugated to K15. Delivered lyophilized peptides were suspended in phosphate glycerol buffer and stored at −20 °C.
Fig. 4 Premature detection of pulmonary inflammation and thrombosis turns into right heart failure. Multi-targeted PFCs for detection of inflammation (red), FXIIIa (cyan) and fibrin (magenta) in the same mouse 5 days (a+b) and 10 days (c) after onset of the diet. a $^{19}$F mCSSI data are superimposed over anatomical $^1$H MRI data (greyscale) and first investigation on day 5 indicated differentially affected tissue sites mainly in pulmonary areas with b normal function in long axis views in diastole and systole (LVEF 70.4%, RVEF 71.1%). The dashed rectangle indicates the perpendicular view shown in a. c Follow-up on day 10 revealed that preceding pulmonary thromboinflammation (a) leads to severe right ventricular impairment (LVEF 54.6%, RVEF 17.8%).

Fig. 5 Occurrence, distribution, and prognostic value of detected $^{19}$F signals. a Occurrence and distribution of detected danger patterns are expressed as percentage of animals affected by inflammation (red), acute (cyan) and chronic (magenta) thrombosis in different anatomical regions ($n = 50$ in 23/17/10 mice on days 5/10/15; LV, RV = left and right ventricle). b Linear regression analysis for detectable $^{19}$F signal at day x and cardiac function at day x+5, i.e. the follow-up investigation five days later ($n = 36$ in 9/17/10 mice on days 5/10/15, adjusted $R^2 = 0.84811$, $P = 2.926 \times 10^{-15}$). The measure of center for the error band is given by the regression line of the linear fit with $y = -0.0004x + 72.816$ and the $P$ value was determined from ANOVA sum of squares. Source data are provided as a source data file.
Fig. 6 Unmasking of emerging danger patterns by multi-targeted PFCs. Schematic drawing of the pathophysiological cascade from beginning coronary inflammation to atherothrombosis and vessel occlusion and the respective epitopes identified by multi-color 19F MRI. Top: Overview of the atherosclerotic continuum from coronary inflammation to occlusion in Hypoe mice upon exposure to atherogenic high-fat diet. White rectangles indicate the magnified areas shown below. Bottom: 1st column: Uptake of injected PFCE droplets by circulating monocytes and early infiltration of 19F-loaded cells into inflamed endothelium; 2nd column: acute thrombosis leads to (i) incorporation of a2AP/PFOB into the developing fibrin network via cross-linking by FXIIIa and (ii) binding of fbnPFCH to fibrin strands; 3rd column: Advanced thrombi are labeled by fbnPFCH only with no detectable signal for a2AP/PFOB due to lack of FXIIa. Acute and advanced thrombosis are accompanied by progressing infiltration of PFCE-loaded monocytes into surrounding tissue; 4th column: Vessel occlusion results in ischemia accompanied by loss of endothelial integrity and late gadolinium enhancement.

Preparation and characterization of perfluorocarbon nanoemulsions (PFCs)

Preparation. PFCs which contained perfluoro-15-crown-5 ether (PFCE), perfluorocyclohexane (PFOB) or perfluoro-1,3,6-trimethylenecyclohexane (PFCH) were prepared by microfluidization with E80S lipids as emulsifier using a laboratory processor (LV1, Microfluidics Corp.) operating at 1000 bar. PFCH and PFOB emulsions were further stabilized by adding (equimolar to the lipid content) a semifluorinated fluorocarbon/hydrocarbon diblock59. In brief, 2.4% (w/w) E80S was dissolved in 10 mM phosphate glycerol buffer. Subsequently, either PFCE (20% w/w), PFCH (40% w/w) or PFOB (40% w/w) was added to the lipid suspension. For PFCH and PFOB 35 mM diblock was additionally added. The suspensions were preemulsified by high shear mixing (Ultra Turrax TP 18/10) and processed with a semi-triplex processor (LV1, Microfluidics Corp.) operating at 1000 bar and for 5 cycles. PFCs were autoclaved (121 °C, 1 bar, 30 min), lacking the scavenger receptor class B type I (SR-BI) and the (c) potential. For this, 20 µl of PFCs were diluted in 1 ml Milli-Q water and analyzed for 90 s. These measurements were repeated for 10 times for calculation of mean values. To gain information on several preparations, the mean values and standard deviations of individual particles measurement were averaged. The characterization of PFCs was determined by dynamic light scattering (DLS) using a Nanotrac instrument (Microtrac) to determine the hydrodynamic diameter, the polydispersity index (PDI) and the number concentration. The suspensions were aliquoted in glass vials, and stored at 4 °C under light protection.

Characterization. PFCs were characterized by dynamic light scattering (DLS) using a Nanotrac instrument (Microtrac) to determine the hydrodynamic diameter, the polydispersity index (PDI) and the number concentration. For this, 20 µl of PFCs were diluted in 1 ml Milli-Q water and analyzed for 90 s. These measurements were repeated for 10 times for calculation of mean values. To gain information on several preparations, the mean values and standard deviations of individual particle size measurements were averaged. For determination of the 19F amount, 10 µl of PFCE, PFOB, PFCH were diluted with 20 µl H2O and filled into a 200 µl reaction tube. Additionally, a 30 µl mixture of PFCs (10 µl each) was prepared. Subsequently, the reaction tubes were fixed to a 2 ml water tube and subjected to 1H/19F MRI (see below).

Functionalization of PFCs. PFCs were equipped with peptide ligands using the sterol-based post-insertion technique (SPTI)55,56. For this, peptides were coupled via free cysteines to cholesterol-PEG2000-maleimide anchors exploiting the formation of a stable thioether after reaction of the cysteine SH-group with the maleimide of the anchor. For conjugation, 280 µg of the peptide (suspended in phosphate glycerol buffer) was added to 300 µl of cholesterol-PEG2000-maleimide (1 µg/µl, suspended in phosphate glycerol buffer) and the volume was adjusted to 650 µl with phosphate glycerol buffer. The solution was incubated overnight at 22 °C under constant stirring. On the next day, 650 µl of the cholesterol-PEG2000-peptide conjugate was mixed with 650 µl of preformed PFCs and incubated at 22 °C for 3 h which led to the spontaneous insertion of the cholesterol conjugate into the lipid layer of the PFC55,56. For targeting of activated platelets, PFCs were equipped with a unique human single-chain antibody (scFv) as previously described28. Functionalized PFCs were stored at 4 °C under light protection.

Ethics. Animal experiments were performed in accordance with the European Union guidelines described in the directive 2010/63/EU and were approved by North Rhine Westphalian State Agency for Nature, Environment and Consumer Protection (LANUV = Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen), Germany. In vitro studies with blood samples from healthy humans were conducted to the declaration of Helsinki and approved by Ethics Committee of the Heinrich Heine University, Düsseldorf, Germany. All healthy volunteers gave written informed consent to the collection and use of blood samples in this study.

Animals. Mice expressing a hypomorphic mutant form of ApoE (ApoE-Rh3/3) and lacking the scavenger receptor class B type I (SR-BI) were bred and housed with a 12:12D cycle (light switch 6:00/18:00) at an ambient temperature of approximately 22 ± 2 °C and a humidity of 55% at the central animal facility of the Heinrich Heine University Düsseldorf, Germany. Mice were fed a standard chow diet and received tap water ad libidum. For induction of the disease model6,17, mice were exposed to a high fat/high cholesterol diet (7.5% cocoa butter, 15.8% fat, 1.25% cholesterol, 0.5% sodium cholate; Altromin). For visualization of thromboinflammatory processes by 19F MRI, mice received an intravenous bolus injection of PFCs (3 mM/kg BW) 48 h prior to MRI to ensure appropriate PFC deposition at the sites of interest6.

A total of 33 mice (males and females, 25–30 g body weight, 8–10 weeks of age) were used in this study. Twenty-three of them were subjected to the main protocol illustrated in Supplementary Fig. 1. All mice received baseline 1H MRI, PFC injections on day 3 after onset of the diet and 1H/19F MRI on day 5. Thereafter, 6 mice were sacrificed for 3D high resolution 1H/19F MRI and histology. For follow-up, 17 mice were subjected to PFC injection on day 8 and 1H/19F MRI on day 10, whereupon again 6 mice were sacrificed for post mortem analyses. Afterwards, one mouse died spontaneously, so that 10 mice received the final PFC injection on day 13 and 1H/19F MRI on day 15. Thereafter, the remaining mice were sacrificed for 3D 1H/19F MRI and pathohistological analyses. Additional 4 mice were used for the explorative study of the fourth color with scFv-PFCs (Supplementary Fig. 15) and further 6 mice served as control and were not subjected to the diet but received PFC injections as indicated above (Supplementary Fig. 7).

Magnetic resonance imaging

General. Data were recorded at a Bruker AVANCE 800DT wide bore NMR spectrometer driven by ParaVision 5.1 (Bruker) and operating at frequencies of 400.21 MHz for 1H and 376.54 MHz for 19F measurements41. Images were acquired using the Bruker microimaging unit Micro 2.5 with actively shielded gradient sets (1.5 T/m) and a
For post mortem high resolutions measurements and subsequent histology, hearts were excised and fixed in a 1.5 ml Eppendorf cap filled with paraformaldehyde. 19F data were acquired with a 3D RARE sequence (RARE factor 32, FOV 22 × 16 × 16 mm3, MS 384 × 256 × 256, TE 21.4 ms, TR 2500 ms, NA 72, TAcq 25.36 s), while anatomical reference data were recorded with a 3D FISP sequence from the same FOV using the following parameters: TE 3.4 ms, TR 6.8 ms, MS 512 × 256 × 256, NA 24, TAcq 51 min. After MRI measurements, serial 5 μm sections of the same piece of heart were cut and stained with hematoxylin and eosin (H&E).

MRI data were imported into 3D visualization software Amira and resampled to isotropic voxel size using a Lanzos filter. 1H MRI data were visualized in grayscale by VRT adapting the lower and upper intensity thresholds for rendering in a way that the surrounding fluid remained invisible. For overlay, the 'flow' colormap was used to render the morphologic corresponding 19F data. After coregistration, data were analyzed in multi-planar view for exact anatomical localization of the 19F label in the hearts. For confirmation of the 19F label to be localized at the luminal site of the aorta (Supplementary Fig. 3), the vessel wall was manually segmented and its surface calculated with unconstrained smoothing. For overlay, semi-transparent surface visualization, the vessel wall was generated and anatomic corresponding 19F data were rendered as described above.

Phantom experiments. To prove reliable quantification of the 19F mCSSI signals, phantom measurements were performed using the same PFCS as in in vivo experiments. PFCS were filled into 200 μl microfluidic tubes and fixed in the reservoirs of in-house constructed specimen holder. MRI data were acquired with same parameters given above and afterwards SNR was determined for each individual excitation frequency (see below).

19F MR image analysis. 19F MRI data were analyzed using an in-house developed software tool that is based on the ImageJ platform (National Institutes of Health) which allowed (i) an overlay on anatomical corresponding 1H MRI data, (ii) an easy separation and image reconstruction for each frequency, and (iii) also a summation of the individual free induction decays to increase SNR for PFCS with multiple signals. For quantification of the 19F signal, ROIs were drawn around the area of interest, whereas background ROIs of similar geometry were placed outside the samples. The signal-to-noise ratio was calculated from the mean of the background-corrected 19F signal divided by the standard deviation of the noise. For phantom measurements, single frequency as well as sum images were quantified from identical ROIs covering the cross sections of the individual PFC-filled vials. For a more detailed description of the 19F MRI approach, acquisition parameters, and quantification procedures, please refer to references 9,64.

Cellular uptake of neat, PEGylated and PEGylated functionalized PFCS

Preparation of Atto647PFCs. Atto647-labeled PFCS were prepared as described above. In brief 100 μg of Atto647-DPPE (DPPE = 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine; ATTO-TEC GmbH) was resuspended in phosphate-glycerol buffer containing solubilized E80S lipids and stirred for 30 min at room temperature. Subsequently, PFCs were added and a pre-emulsion was generated by high shear mixing. The crude emulsion was subjected to five cycles of microfluidization (LV1, Microfluidics) at 1000 bar.

PEGylation and functionalization of PFCS. PEGylated PFCS were generated by incubation of 100 μl of Atto647PFCS with 100 μl of cholesterol-PEG2000-CH3 (45 μl PEG + 55 μl buffer). To generate ligand-functionalized PFCS, Fbn or α2AP were conjugated to cholesterol-PEG2000-maleimide and then inserted into the lipid surface of the PFCS by SPT. To this end, 12.2 μl Fbn or 13.4 μl α2AP (2.5 μg/ml each) were incubated with 39.2 μl cholesterol-PEG2000-maleimide. The volume was adjusted to 100 μl with phosphate glycerol buffer and incubated overnight at 20 °C under constant motion. On the next day, 100 μl of the Fbn/α2AP conjugate and additional 12 μl of cholesterol-PEG2000-CH3 (10 μg/ml) were added to 100 μl of Atto647PFCS and incubated for 3 h at 20 °C.

Cellular uptake of PFCs by RAW macrophages and murine monocytes. RAW macrophages were detached from the culture flask by strong shaking of the flask. Approximately 5 × 105 cells were taken up in 500 μl of culture medium and incubated with 25 μl of PFCs at 37 °C for 20 min. Subsequently, cells were transferred into a FACS tube filled with 1 ml of ice cold FACS buffer (PBS, 2% FBS, 1% EDTA). Cells were washed, finally resuspended in 500 μl FACS buffer with DAPI (1 μg/ml; to label dead cells) and analyzed on a FACS Canto II (BD Biosciences). For analysis of PFC uptake by murine monocytes, blood was obtained by venous puncture of heparinized mice. Subsequently, the withdrawn blood (~100 μl) was subjected to hypotonic erythrocyte lysis (3 ml) for 5 min at room temperature, followed by centrifugation. The pellet was washed twice with ice cold FACS buffer. Incubation with PFCs was again carried out for 20 min at 37 °C. Afterward, cells were washed and labeled with antibodies against CD11b (CD11b-PE, clone M1/17; BD Biosciences) and Ly6G (Ly6G-FITC, clone 1A8, BioLegend) for 30 min at room temperature, pelletled by centrifugation and washed with ice cold FACS buffer. Incubation with PFCs was again carried out for 20 min at 37 °C. Afterward, cells were washed and labeled with antibodies against CD11b (CD11b-PE, clone Ly6G-2F10, BD Biosciences) and Ly6G (Ly6G-FITC, clone 1A8, BioLegend) for 30 min at 4 °C, washed twice with FACS buffer, stained with DAPI and analyzed by flow cytometry. For cellular uptake of neat, PEGylated and PEGylated functionalized PFCS, data were acquired. Mean fluorescence signals of RAW macrophages and murine monocytes were recorded in the APC channel and fluorescence signals of cells which were not exposed to PFCs...
were subtracted from the data of cells incubated with neat, PE-Glylated, and PE-Glylated functionalized PFCs. Please refer to Supplementary Fig. 16 for the gating scheme used to analyze RAW macrophages and murine monocytes.

**In vitro generation and labeling of thrombi.** Platelet rich plasma (PRP) was obtained by venous puncture from healthy volunteers and immediately centrifuged at 200 × g for 10 min. The white PRP on the top of the sample was carefully withdrawn, separated in 1 ml aliquots and stored at −20 °C. For generation of acute thrombi, 1 ml of the PRP was melted on ice and mixed with 100 µl of thrombin (5 U/ml) and 10 µl of ADP (1 mM). Then 100 µl samples were transferred to wells of a round-bottom 96-well plate and incubated for 5 min. Next, a2APP/FOB or δAPP/FCCH were added and incubated for additional 90 min. Thrombi were removed and washed three times with 5 ml of PBS and analyzed by IVIS (see below) or 19F MRI. To obtain subacute thrombi, PRP was activated with thrombin and ADP (as described above) and 100 µl samples were incubated in a round-bottom 96-well plate for 90 min. Formed thrombi were removed from the well, washed with PBS and incubated with fn or ctr peptide or δAPP/FCCH/α2APP/FOB (for the respective controls). To determine the binding of PFCs to chronic thrombi, thrombi were stored in PBS for 24 h, three days and five days at 4 °C and then incubated with the targeting probes, intensively washed with PBS and analyzed by IVIS.

**Imaging of in vitro generated thrombi.** Thrombi labeled with fn/a2AP- peptides or δAPP/FCCHs were spotted on a glass plate and the fluorescence signal of the carboxyfluorescein was determined by an IVIS Lumina II imaging system (Perkin Elmer). For quantification, ROIs were drawn around the thrombus-associated fluorescence signals and the background-corrected mean values were determined. For 19F MRI, thrombi were placed in 200 µl reaction tubes filled with PBS which were fixed at a 2 ml water tube.

**Induction of deep venous thrombi in vivo.** Mice were kept under anesthesia with 1.5% isoflurane and buprenorphin (0.3 mg/kg) was injected s.c. 30 min prior to surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a surgery for analgesia. A median laparotomy was per...
49. Bulte, J. W. M. et al. MR cholangiography demonstrates unsuspected rapid
50. Spahn, D. R. Blood substitutes. Artif.
51. Tirotta, I. et al. A super
52. Ahrens, E. T., Helfer, B. M., O
53. Keupp, J. et al. Simultaneous dual-nuclei imaging for motion corrected
54. Overoye-Chan, K. et al. EP-2104R: a fibrin-specific gadolinium-Based MRI
55. Keupp, J. et al. Simultaneous dual-nuclei imaging for motion corrected

56. Ovolye-Chan, K. et al. T1-weighted magnetic resonance imaging as a novel determinant of coronary events, J. Am. Coll. Cardiol. 63, 989–999 (2014).

57. Oikonomou, E. K. et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 392, 929–939 (2018).

58. Wakeman, R. et al. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study. Lancet 394, 1629–1637 (2019).

59. Jacoby, C. & Flögel, U. MR for the investigation of murine vasculature. Methods Mol. Biol. 771, 439–456 (2011).

60. Gheibihayat, S. M., Jaafari, M. R., Hatamipour, M. & Sahebkar, A. 19F-MRI. Eur. Heart J. 36(Suppl 2), S104 – S106 (2015).

61. Castro, C. I. & Briceno, J. C. Perturbed and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Am. J. Transplant. 11, 235–244 (2011).

62. Ahrens, E. T., Helfer, B. M., O. Department of Radiology, University Hospital of Zürich, Switzerland.

63. Overoye-Chan, K. et al. EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J. Am. Coll. Cardiol. 130, 6025–6039 (2008).

64. Kolsodzie, A. F., Zhang, Z., Overoye-Chan, K., Jacques, V. & Caravan, P. Peptide optimization and conjugation strategies in the development of molecularly targeted magnetic resonance imaging contrast agents. Methods Mol. Biol. 1088, 185–211 (2014).

65. Flögel, U. et al. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci. Transl. Med. 4, 146ra108 (2012).

66. Flögel, U. et al. Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci. Transl. Med. 4, 146ra108 (2012).

67. Garcia, G. et al. Improved control over particle sizes and stability of concentrated fluorocarbon emulsions by using mixed fluorocarbon/hydrocarbon molecular fluids. Artif. Cells Blood Substit. Immobil. Biotechnol. 22, 1183–1191 (1994).

68. Gantert, M. et al. Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors. Pharm. Res. 26, 529–538 (2009).

69. Mehta, J. P. et al. Comparison between prospective and retrospective triggering for mouse cardiac MRI. NMR in Biomed. 20, 439–448 (2007).

70. Neumann, F.-J. et al. 2018 ESC/EACTS guidelines on myocardial infarction and acute coronary syndromes. Eur. Heart J. 41, 411–477 (2020).